Conversely, silencing Raf1 by shRNAs or using U0126, a MEK1 specific inhibitor, dramatically abrogates the promotive effect of PAK1 on ESCC cells. This evidence concerns the gene MAP2K1 and esophageal squamous cell carcinoma.